In summary, we have demonstrated the effectiveness of simultaneous blockade of TGFβ and PD-L1 in mouse SCC models, targeting both TGFβ-secreting tumor cells and PD-L1+ myeloid cells within the tumor (Fig. 8a, b). The gene discussed is TGFB1; the disease is neoplasm.